Harvard Bioscience (HBIO) director awarded 16,556 RSUs in new grant

Rhea-AI Filing Summary

Gagnon Robert E. reported acquisition or exercise transactions in this Form 4 filing.

Harvard Bioscience director Robert E. Gagnon received an equity grant of 16,556 restricted stock units (RSUs) of common stock. The award vests in full immediately before the company’s next annual meeting or one year from the grant date, whichever occurs first.

After this grant, Gagnon beneficially owns 27,556 common shares, including 11,000 shares previously issued upon vesting of earlier RSUs. Those 11,000 shares were adjusted to reflect a 10-for-1 reverse stock split of Harvard Bioscience common stock that took place on March 13, 2026.

Insights

Equity Compensation Analyst

Director received routine RSU grant with clear vesting terms.

The filing shows Robert E. Gagnon, a director of Harvard Bioscience, acquiring 16,556 RSUs at no cash cost as a compensation award. Such grants are common tools for aligning director incentives with shareholder interests through equity-based pay.

The RSUs vest in a single tranche either before the next annual meeting or one year from grant, concentrating vesting into a near-term event. Following the award, Gagnon holds 27,556 shares, indicating this is a modest, routine update rather than a large directional bet or sale.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Gagnon Robert E.

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	16,556	$0.00	--

Holdings After Transaction: Common Stock — 27,556 shares (Direct, null)

Footnotes (1)

1. Represents an award of 16,556 restricted stock units that vests in full (i) immediately prior to the Company's next annual meeting; or (ii) one year from the date of grant, whichever is earlier. Includes (a) the award described in footnote (1) above and (b) 11,000 shares of common stock beneficially owned by the Reporting Person. On March 13, 2026, the common stock of Harvard Bioscience, Inc. underwent a reverse stock split in a ratio of 10-for-1. The 11,000 shares referenced in Footnote 2(b) were previously reported as covering 110,000 restricted stock units (which have now vested) and are beneficially owned by the Reporting Person. These numbers have been adjusted to reflect the stock split that occurred on March 13, 2026.

Key Figures

RSU grant: 16,556 RSUs Shares after transaction: 27,556 shares Previously held shares: 11,000 shares +2 more

5 metrics

RSU grant 16,556 RSUs Director equity award of common stock

Shares after transaction 27,556 shares Total beneficial ownership following grant

Previously held shares 11,000 shares Shares from earlier vested RSUs, post-split

Reverse stock split ratio 10-for-1 Common stock split on March 13, 2026

Grant price per share $0.00 per share Compensation grant, no cash paid by director

Key Terms

restricted stock units, reverse stock split, beneficially owned

3 terms

restricted stock units financial

"Represents an award of 16,556 restricted stock units that vests in full"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

reverse stock split financial

"underwent a reverse stock split in a ratio of 10-for-1"

A reverse stock split is when a company reduces the number of its shares outstanding, making each share more valuable. For example, if you own 100 shares worth $1 each, a 1-for-10 reverse split would turn your 100 shares into 10 shares worth $10 each. Companies often do this to boost their stock price and appear more stable to investors.

beneficially owned financial

"11,000 shares of common stock beneficially owned by the Reporting Person"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gagnon Robert E.

(Last) (First) (Middle)

C/O HARVARD BIOSCIENCE, INC.

84 OCTOBER HILL ROAD

(Street)

HOLLISTON MASSACHUSETTS

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
HARVARD BIOSCIENCE INC [ HBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/09/2026		A		16,556(1)	A	$0.00	27,556(2)(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents an award of 16,556 restricted stock units that vests in full (i) immediately prior to the Company's next annual meeting; or (ii) one year from the date of grant, whichever is earlier.

2. Includes (a) the award described in footnote (1) above and (b) 11,000 shares of common stock beneficially owned by the Reporting Person.

3. On March 13, 2026, the common stock of Harvard Bioscience, Inc. underwent a reverse stock split in a ratio of 10-for-1. The 11,000 shares referenced in Footnote 2(b) were previously reported as covering 110,000 restricted stock units (which have now vested) and are beneficially owned by the Reporting Person. These numbers have been adjusted to reflect the stock split that occurred on March 13, 2026.

	/s/ Robert Gagnon	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did HARVARD BIOSCIENCE (HBIO) director Robert Gagnon report?

Director Robert E. Gagnon reported receiving an award of 16,556 restricted stock units of Harvard Bioscience common stock. The RSUs were granted at no cash cost as part of his director compensation, increasing his total beneficial ownership reported in this filing.

How many HARVARD BIOSCIENCE (HBIO) shares does Robert Gagnon own after this Form 4?

After the reported grant, Robert Gagnon beneficially owns 27,556 shares of Harvard Bioscience common stock. This total includes the new 16,556 restricted stock units and 11,000 previously issued shares that resulted from earlier vested RSU awards adjusted for a prior reverse split.

What are the vesting terms of Robert Gagnon’s new HARVARD BIOSCIENCE RSU award?

The 16,556 restricted stock units granted to Robert Gagnon vest in full in a single event. Vesting occurs immediately before Harvard Bioscience’s next annual meeting or one year from the grant date, whichever happens earlier, tying the award’s timing to board service and corporate governance events.

How did HARVARD BIOSCIENCE’s reverse stock split affect Robert Gagnon’s reported holdings?

Harvard Bioscience completed a 10-for-1 reverse stock split on March 13, 2026. Gagnon’s 11,000 reported shares were previously shown as 110,000 restricted stock units that have since vested, and the filing explains that these figures have been adjusted to reflect the reverse split’s impact.

Was Robert Gagnon’s HARVARD BIOSCIENCE transaction a market purchase or sale?

The transaction was not a market purchase or sale. It reflects a grant or award of 16,556 restricted stock units at a stated price of $0.00 per share, indicating compensation-related equity rather than an open-market trade initiated by the director.